UC2288

Overview

UC2288 is a potent and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib ( HY-10201 ). UC2288 potently inhibits cancer cell growth by inducing apoptosis . UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM.

Application

Products | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > MDM-2/p53 | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-112780
• CAS No.: 1394011-91-6
• Molecular Formula: C20H18ClF6N3O2
• Molecular Weight: 481.82
• Purity: 99.78%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.08 mg/mL (4.32 mM); Clear solution
• Availability: In-stock

Source

Original product source